Pilot Study of Preoperative Combined Modality Treatment for Locally Advanced Operable Oesophageal Carcinoma: Toxicities and Long-term Outcome

Clinical Oncology

Volumn 18, Issue 4, 2006, Pages 338-344

  Mukherjee, S ^a   Abraham, J ^a   Brewster, A ^a   Hardwick, R ^b   Havard, T ^c   Lewis, W ^d   Askill, C ^e   Manson, J ^e   Williams, G T ^b   Roberts, S A ^b   Court, J ^a   Crosby, T ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c ROYAL GLAMORGAN HOSPITAL   (United Kingdom)

^d ROYAL GWENT HOSPITAL   (United Kingdom)

^e SINGLETON HOSPITAL   (United Kingdom)

Author keywords

Chemoradiation; paclitaxel; pre operative; response rate; toxicity

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AORTOESOPHAGEAL FISTULA; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG INFUSION; ESOPHAGITIS; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HOSPITAL ADMISSION; HUMAN; LAPAROTOMY; MALE; MEDIASTINITIS; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PHLEBITIS; PILOT STUDY; PREOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; SEPSIS; STOMATITIS; THORACOTOMY; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS;

EID: 33645882541     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.12.009     Document Type: Article

References (26)

1. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 49 (1999) 8-31
2. Pye J.K., Crumlin M.K., Charles J., Kerwat R., Foster M.E., and Biffin A. Hospital clinicians in Wales. One-year survey of carcinoma of the oesophagus and stomach in Wales. Br J Surg 88 (2001) 278-285
3. Blazeby J., Farndon J., Donovan J., and Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 88 (2000) 1781-1787
4. Medical Research Council (MRC) Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359 (2002) 1727-1733
5. Geh J.I., Crellin A.M., and Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 88 (2001) 338-356
6. Urschel J.D., and Vasan H. A meta-analysis of randomised controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185 (2003) 538-543
7. Ajani J.A., Ilson D.H., Daugherty K., et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86 (1994) 1086-1091
8. Polee M.B., Tilanus H.W., Eskens F.A., et al. Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the oesophagus. Ann Oncol 14 (2003) 1253-1257
9. Wahl A.F., Donaldson K.L., Fairchild C., et al. Loss of normal p53 functions confers sensitisation to Taxol by increasing G2/M arrest and aoiotisus. Nat Med 2 (1996) 72-79
10. Mason K.A., Milas L., and Peters L.I. Effect of paclitaxel (taxol) alone and in combination with radiation of the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys 32 (1995) 1381-1389
11. Toy E.W., Crosby T.D., Bowrey D.J., et al. Neoadjuvant chemoradiotherapy in carcinoma of the oesophagus. Br J Cancer 78 Suppl 2 (1998) Proc BOA 22(067)
12. Kelsen D.P., Ginsberg R., Pajak T.F., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339 (1998) 1979-1984
13. Walsh T.N., Noonan N., Hollywood D., et al. A comparison of multimodality therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335 (1996) 462-467
14. Bossett J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337 (1997) 161-167
15. Suntharalingam M., Moughan J., Coia L.R., et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys 56 (2003) 981-987
16. Wright C.D., Wain J.C., Lynch T.J., et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg 114 (1997) 811-816
17. Adelstein D.J., Rice T.W., Rybicki L.A., et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 18 (2000) 2032-2039
18. Schnirer I.I., Komaki R., Yao J., et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 24 (2001) 91-95
19. Ajani J.A., Komaki R., Putnam J.B., et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92 (2001) 279-286
20. Safran H., Galssert H., Akerman P., et al. Paclitaxel, cisplatin and concurrent radiation for esophageal cancer. Cancer Invest 19 (2001) 1-7
21. Bains M.S., Stojadinovic A., Minsky B., et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg 124 (2002) 270-277
22. Meluch A., Greco A., Gray J.R., et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network Phase II Trial. Cancer J 9 (2003) 251-260
23. Goldberg M., Farma J., Lampert C., et al. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in respectable esophageal carcinoma: a phase I report. J Thorac Cardiovasc Surg 126 (2003) 1168-1173
24. Crosby T.D., Brewster A.E., Borley A., et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 90 (2004) 70-75
25. Muller J.M., Erasmi H., Stelzner M., Zieren U., and Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg 77 (1990) 845-857
26. Mukherjee S., Aston D., Minnett M., Brewster A.E., and Crosby T.D.L. The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers. Clin Oncol 15 (2003) 115-120